Floatz logo

92 assets in Cholangiocarcinoma

Therapeutic assets addressing Cholangiocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Spartalizumab
Cholangiocarcinoma
SOLTI Breast Cancer Research GroupP2CC (46)
Avelumab
Cholangiocarcinoma
National Cancer Institute (NCI)P1/2CC (45)
ab-218
Cholangiocarcinoma
AnHeart Therapeutics Inc.P1CC (43)
Allogeneic Natural Killer Cells
Cholangiocarcinoma
Medigen Biotechnology CorporationP1/2CC (43)
Apl-5125
Cholangiocarcinoma
Apollo Therapeutics LtdP1/2CC (43)
au409
Cholangiocarcinoma
University of Southern CaliforniaP1CC (43)
bnt141
Cholangiocarcinoma
BioNTech SEP1/2CC (43)
Bold-100
Cholangiocarcinoma
Bold Therapeutics, Inc.P1/2CC (43)
cgt4859
Cholangiocarcinoma
Cogent Biosciences, Inc.P1/2CC (43)
ct-95
Cholangiocarcinoma
Context Therapeutics Inc.P1CC (43)
Gavo-Cel
Cholangiocarcinoma
TCR2 TherapeuticsP1/2CC (43)
Guadecitabine
Cholangiocarcinoma
University of Southern CaliforniaP1CC (43)
Ligritinib
Cholangiocarcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Neoantigen Specific Tcr-T Cell Drug Product
Cholangiocarcinoma
Alaunos TherapeuticsP1/2CC (43)
ngm707
Cholangiocarcinoma
NGM Biopharmaceuticals, IncP1/2CC (43)
Synkir-110, Autologous T Cells Transduced With Mesothelin Kir-Car
Cholangiocarcinoma
Verismo TherapeuticsP1CC (43)
tc-510
Cholangiocarcinoma
TCR2 TherapeuticsP1/2CC (43)
Tyra-200
Cholangiocarcinoma
Tyra Biosciences, IncP1CC (43)
Cabotamig
Cholangiocarcinoma
Arbele Pty LtdP1CC (42)
Cdx-585
Cholangiocarcinoma
Celldex TherapeuticsP1CC (42)
Eli-002 7P
Cholangiocarcinoma
Elicio TherapeuticsP1CC (42)
Monoclonal Antibody Trk-950
Cholangiocarcinoma
Toray Industries, IncP1CC (42)
Recombinant Ephb4-Hsa Fusion Protein
Cholangiocarcinoma
University of Southern CaliforniaP1CC (42)
ACETIC
Cholangiocarcinoma
M.D. Anderson Cancer CenterP1C (39)
Adriamycin
Cholangiocarcinoma
Toray Industries, IncP1C (39)
Cea Car-T Cells
Cholangiocarcinoma
Chongqing Precision Biotech Co., LtdP1C (39)
Cea-Targeted Car-T
Cholangiocarcinoma
Chongqing Precision Biotech Co., LtdP1C (39)
cf33-hnis
Cholangiocarcinoma
Imugene LimitedP1C (39)
Felmetatug Vedotin
Cholangiocarcinoma
Seagen, a wholly owned subsidiary of PfizerP1C (39)
[Ga-68]-Pnt6555
Cholangiocarcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyP1C (39)
Imiquimod
Cholangiocarcinoma
Toray Industries, IncP1C (39)
[Lu-177]-Pnt6555
Cholangiocarcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyP1C (39)
LY 3410738
Cholangiocarcinoma
Eli Lilly and CompanyP1C (39)
ly4337713
Cholangiocarcinoma
Eli Lilly and CompanyP1C (39)
mgc028
Cholangiocarcinoma
MacroGenicsP1C (39)
ngm438
Cholangiocarcinoma
NGM Biopharmaceuticals, IncP1C (39)
ngm831
Cholangiocarcinoma
NGM Biopharmaceuticals, IncP1C (39)
Phst001
Cholangiocarcinoma
Pheast TherapeuticsP1C (39)
tcr1188-abc cells
Cholangiocarcinoma
University of PennsylvaniaP1C (39)
Tocilizumab
Cholangiocarcinoma
University of PennsylvaniaP1C (39)
Wm-A1-3389
Cholangiocarcinoma
Wellmarker BioP1C (39)
Ceralasertib
Cholangiocarcinoma
National Cancer Institute (NCI)P2NR ()
Showing 51 to 92 of 92 assets
PreviousPage 2 of 2Next